{"gene":"C1S","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1977,"finding":"Activated C1s (C̄1s) consists of two polypeptide chains of ~56 kDa ('a' chain) and ~27 kDa ('b' chain); the 'b' chain bears the serine protease domain with trypsin-like homology. C1s hydrolyzes lysine ester bonds and cleaves C1s substrate C4 but does not cleave amino acid esters nor protein substrates other than those in the complement cascade, demonstrating its narrow specificity. Activated C1r cleaves C1s to generate the two-chain active form.","method":"SDS-PAGE, amino acid sequencing, N-terminal sequence analysis, esterolytic activity assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic characterization with sequencing, replicated across multiple labs over decades","pmids":["869924"],"is_preprint":false},{"year":1977,"finding":"C1s cleaves C2 into two antigenically distinct fragments: C2a (73 kDa, larger, more acidic) and C2b (34 kDa, smaller, more basic). C2b contains the C4b-binding site and remains associated with C4b after C2a decay-release from the C3 convertase.","method":"In vitro cleavage assay, disc electrophoresis, immunoelectrophoresis, C4b-Sepharose binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with solid-phase binding assay, foundational biochemical study","pmids":["70787"],"is_preprint":false},{"year":1975,"finding":"C1 inhibitor forms a stable 1:1 molar SDS/urea-resistant complex with C1s via the light chain of C1s. Complex formation requires native (non-denatured) C1 inhibitor conformation. Plasmin degrades C1 inhibitor but at least one derivative retains the ability to complex C1s.","method":"SDS-PAGE, size-exclusion chromatography, enzyme activity assays, acid denaturation controls","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro biochemical reconstitution with multiple orthogonal methods; foundational mechanism paper","pmids":["123251"],"is_preprint":false},{"year":2000,"finding":"Crystal structure of the C1s catalytic fragment (CCP2 + serine protease domain) resolved to 1.7 Å. The SP domain shows restricted access to subsidiary substrate binding sites, explaining narrow specificity. The CCP2 module is oriented perpendicularly to the SP domain surface via a rigid interface involving proline- and tyrosine-rich segments, and CCP2 provides additional substrate recognition sites for C4.","method":"X-ray crystallography at 1.7 Å resolution","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with functional interpretation; single rigorous paper","pmids":["10775260"],"is_preprint":false},{"year":1987,"finding":"The complete amino acid sequence of human C1s (673 residues + 15-residue leader) was determined from cDNA. The N-terminal chain (422 residues) contains five domains including two EGF-like repeats, two CCP modules, and domains homologous to C1r. The C-terminal chain (251 residues) is the serine protease domain.","method":"cDNA cloning and nucleotide sequencing from human liver library, supported by amino acid sequence data","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — complete sequence determination with independent amino acid sequence validation","pmids":["3500856"],"is_preprint":false},{"year":2003,"finding":"Crystal structure of the C1s CUB1-EGF interaction domain resolved to 1.5 Å reveals a head-to-tail homodimer; Ca2+ is bound to the EGF module stabilizing intra- and inter-monomer interfaces. A second Ca2+ is bound to the CUB1 module via Glu45, Asp53, Asp98, defining a novel Ca2+-binding CUB module subset. This domain mediates Ca2+-dependent C1r-C1s association and C1q interaction.","method":"X-ray crystallography at 1.5 Å, Ca2+ coordination analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with detailed mechanistic interpretation of Ca2+ binding and protein-protein interaction","pmids":["12788922"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of a zymogen C1s construct (CCP1-CCP2-SP) reveals that two loops (492–499 and 573–580) in the zymogen SP domain adopt a conformation that sterically abrogates C4 binding. Activation repositions these loops to interact with sulfotyrosine residues on C4. SPR confirmed that only active C1s (not zymogen) binds C4. The CCP1-CCP2 junction constitutes an exosite for C4 recognition.","method":"X-ray crystallography, surface plasmon resonance (SPR)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with SPR binding assay, two orthogonal methods in one rigorous study","pmids":["23592783"],"is_preprint":false},{"year":2013,"finding":"C1q collagen-like stems bind C1s (and C1r) via a Ca2+-dependent mechanism involving a lysine side chain (critical residues LysB61 and LysC58 of C1q contacting acidic Ca2+-coordinating residues in C1r/C1s CUB modules). In C1, C1s forms a compact ring-shaped tetramer with a unique head-to-tail interaction at its center, enabling activation by C1r and access to substrates C4 and C2.","method":"X-ray crystallography (C1s–collagen peptide complex; C1s tetramer), SPR mutagenesis validation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures plus SPR mutagenesis, comprehensive structural characterization","pmids":["23922389"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of the C1r-C1s CUB1-EGF-CUB2 heterodimer reveals an antiparallel L-shaped arrangement with Ca2+ at the interface from each subcomponent. Contacts involve all three domains of each protease and are more extensive than homodimers, explaining preferential heterocomplex formation. In C1, two C1r-C1s dimers are linked via the C1r catalytic domains; activation is driven by separation of the dimer pairs upon C1q surface binding.","method":"X-ray crystallography, biophysical analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure of the C1r-C1s heterodimer with functional model, single rigorous paper","pmids":["29311313"],"is_preprint":false},{"year":1998,"finding":"Both CCP modules of C1s are required for efficient C4 cleavage: deletion of CCP1 reduces C4-cleaving activity ~70-fold and deletion of both CCP modules abolishes it. C2 cleavage is minimally affected by CCP deletion. The carbohydrate moiety on CCP2 has no significant effect on catalytic activity.","method":"Baculovirus expression of truncated recombinant C1s fragments, functional cleavage assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted recombinant domain-deletion analysis with quantitative substrate cleavage assays","pmids":["9422791"],"is_preprint":false},{"year":2005,"finding":"Phage display randomized library profiling revealed that C1s substrate specificity is determined primarily by the P1 position (Arg/Lys), followed by P3 (Leu/Val preferred) and P2 (Gly/Ala preferred), with the S2' position preferring Leu. Prime subsites collectively contribute to cleavage efficiency.","method":"Randomized phage display library, kinetic substrate assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic substrate library screening with kinetic validation; comprehensive active-site specificity mapping","pmids":["16169853"],"is_preprint":false},{"year":2012,"finding":"Four positively charged residues on the C1s SP domain form a catalytic exosite required for efficient C4 cleavage; these residues coordinate a sulfate ion in the crystal structure. C1s interacts with a peptide from C4 containing three sulfotyrosine residues via this exosite.","method":"Site-directed mutagenesis, crystal structure analysis, peptide binding assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with structural and biochemical peptide binding data in a single study","pmids":["22855709"],"is_preprint":false},{"year":2009,"finding":"C1r CUB1 and CUB2 modules provide high-affinity C1q-binding sites, and C1s CUB1 provides lower-affinity sites; all sites involve acidic residues that also contribute Ca2+ ligands. Together the C1s-C1r-C1r-C1s tetramer contributes six C1q-binding sites, one per C1q stem. A previous model invoking ionic bonds from the C1r EGF Glu137-Glu-Asp139 stretch was ruled out by mutagenesis.","method":"Site-directed mutagenesis of C1r/C1s, SPR binding assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic mutagenesis with quantitative SPR, refuting prior model and establishing new one","pmids":["19473974"],"is_preprint":false},{"year":2000,"finding":"C1s is the serine protease secreted by human fibroblasts that cleaves insulin-like growth factor-binding protein-5 (IGFBP-5) but not IGFBP-1 through -4. C1r undergoes autoactivation in fibroblast medium and the activated form cleaves C1s; the activated C1s cleaves both C4 and IGFBP-5. C1 inhibitor inhibits this IGFBP-5 cleavage.","method":"Protein purification, immunoaffinity chromatography, amino acid sequencing, IGFBP-5 zymography, C4 cleavage assay, C1 inhibitor inhibition assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — purification with sequence confirmation, multiple functional assays including inhibitor control","pmids":["10982804"],"is_preprint":false},{"year":1990,"finding":"Activated C1s cleaves beta2-microglobulin at Lys-58, generating a two-chain modified form; this is the first demonstrated non-complement protein substrate for C1s. Cleavage is inhibited by C1 esterase inhibitor.","method":"In vitro protease assay, mass spectrometry (sequence analysis of cleavage products), C1 esterase inhibitor inhibition","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro cleavage with product characterization and inhibitor control","pmids":["2110898"],"is_preprint":false},{"year":2016,"finding":"C1s (both purified and as part of the C1 complex) cleaves the nuclear alarmin HMGB1 into defined 19 kDa and 12 kDa fragments, diminishing HMGB1's ability to enhance LPS-mediated pro-inflammatory cytokine production from monocytes, macrophages and dendritic cells. Mass spectrometry of C1 complex-treated apoptotic cell proteins identified additional intracellular C1s substrates.","method":"In vitro protease assay with purified C1s and C1 complex, SDS-PAGE, mass spectrometry, cytokine production assay","journal":"Cell death discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro cleavage confirmed with both purified enzyme and physiological C1 complex, functional consequence measured","pmids":["27648302"],"is_preprint":false},{"year":1992,"finding":"C1s undergoes Ca2+-dependent self-association to form a dimer. The monomer has a single Ca2+-binding site (K ~3×10^5 M^-1); the dimer has three Ca2+-binding sites, with one high-affinity interfacial site (K ~1×10^8 M^-1) driving dimerization.","method":"Sedimentation equilibrium ultracentrifugation over wide concentration ranges","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative biophysical measurement with full thermodynamic model","pmids":["1445906"],"is_preprint":false},{"year":1986,"finding":"C1s inhibition by C1 inhibitor follows pure second-order kinetics with a bimolecular rate constant of 6.0×10^4 M^-1 s^-1 at 30°C, forming a covalent complex. Heparin accelerates the rate up to 35-fold and binds all three components (enzyme, inhibitor, complex) with similar affinity (Kd 2.0–3.3 μM).","method":"Continuous esterolytic activity monitoring, HPLC size-exclusion chromatography, fluorescence probes","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal kinetic methods, quantitative characterization of inhibition mechanism","pmids":["3091067"],"is_preprint":false},{"year":1988,"finding":"The B chain (serine protease domain) of C1s is structurally and functionally independent of the A chain interaction domain. A C1s derivative lacking most of the B chain (C1s-A) retains the ability to dimerize, form C1r2s2 tetramers, and associate with C1q, but is catalytically inactive. All C1q- and C1r-binding sites of C1s are located on the A chain.","method":"Trypsin-limited proteolysis, fast exclusion chromatography, thermal denaturation fluorimetry, functional reconstitution hemolytic assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain-deletion approach with multiple functional readouts demonstrating structural independence","pmids":["2847785"],"is_preprint":false},{"year":1997,"finding":"C1-inhibitor–C1s complexes are cleared in vivo via the low density lipoprotein receptor-related protein (LRP). Cellular degradation of C1-INH·C1s is inhibited by chloroquine and by receptor-associated protein (RAP, an LRP inhibitor); LRP-deficient fibroblasts do not degrade the complex. C1-INH·C1s does not stimulate neutrophil or monocyte chemotaxis.","method":"Cell binding assays (HepG2, neutrophils, monocytes), in vivo clearance with RAP inhibition, LRP-knockout fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacologic dissection with LRP-deficient cells; two orthogonal methods","pmids":["9388254"],"is_preprint":false},{"year":1994,"finding":"C1s activates the zymogen of matrix metalloproteinase 9 (MMP-9), suggesting coordinated participation of C1s and MMP-9 in cartilage matrix degradation.","method":"Immunohistochemistry, in vitro zymogen activation assay","journal":"Cell and tissue research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single in vitro activation assay supported by immunolocalization; single lab, limited functional follow-up","pmids":["8082118"],"is_preprint":false},{"year":2005,"finding":"Chimeric C1s/MASP-2 molecules show that higher C4 cleavage efficiency of MASP-2 arises from the CCP modules (nanomolar vs micromolar Km with C4). C2 cleavage efficiency is determined by the SP domain. C1s CCP modules are not required for C1r binding, C1q association, or tetramer assembly.","method":"Baculovirus expression of chimeric proteins, kinetic substrate cleavage assays, C1 complex reconstitution","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — domain-swap chimeras with quantitative kinetic analysis and functional reconstitution","pmids":["16227207"],"is_preprint":false},{"year":1992,"finding":"Recombinant C1s lacking beta-hydroxyasparagine at Asn134, sialic acid, and one N-linked carbohydrate chain (Asn159→Gln mutant) still reassembles with C1q and C1r to form functional C1 and initiates the classical complement pathway, demonstrating these post-translational modifications are not critical for C1 assembly or activation.","method":"Baculovirus expression, site-directed mutagenesis, sedimentation analysis, hemolytic assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct mutagenesis with functional reconstitution assay","pmids":["1533159"],"is_preprint":false},{"year":1987,"finding":"On cardiolipin (CL) vesicles, C1s can be activated independently of C1r: a C1q-dependent, Ca2+-sensitive binding of dimeric C1s to CL vesicles occurs, and bound C1s is specifically cleaved at 37°C into active 58 kDa and 28 kDa chains in the absence of C1r. Anti-CL antibodies inhibit this C1q-mediated C1s cleavage.","method":"Immunochemical analysis, SDS-PAGE, complement activation assays with C1 component depletion","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, biochemical fractionation with specific antibody inhibition controls, but unusual mechanism with limited replication","pmids":["3029222"],"is_preprint":false},{"year":1999,"finding":"Active C1s (detected by activation-specific antibody M241) is present in degenerating cartilage of rheumatoid arthritis but not osteoarthritis. TNF-alpha increases C1s production by chondrocytes in vitro. Activated C1s in cartilage is proposed to participate in pathogenesis through collagenolytic activity.","method":"Immunohistochemistry with activation-state-specific monoclonal antibody, ELISA for cytokine regulation","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — in situ detection with activation-specific antibody and cytokine regulation experiment; functional mechanism inferred not directly demonstrated in cartilage","pmids":["10364916"],"is_preprint":false},{"year":1983,"finding":"C1s is synthesized and secreted by resting human monocytes; stimulation by lymphokine-conditioned media increases C1s secretion and also induces C1r and C1 inhibitor secretion. The whole C1 complex can potentially be assembled locally.","method":"Metabolic labeling, immunoprecipitation, SDS-PAGE, functional complement assays from monocyte cultures","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biosynthesis demonstrated by metabolic labeling and secretion assays; multiple cell conditions tested","pmids":["6318736"],"is_preprint":false},{"year":1998,"finding":"Anti-C1-inhibitor autoantibodies prevent formation of stable covalent C1s–C1 inhibitor complexes by converting C1 inhibitor to a substrate: C1s cleaves C1 inhibitor but a stable covalent bond does not form. Peptides 2 (aa 438–449) and 3 (aa 448–459) of C1 inhibitor block autoantibody activity and restore C1s inhibition.","method":"SDS-PAGE complex analysis, esterolytic activity assays, peptide competition assays","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays with peptide competition confirming mechanism; single lab","pmids":["9508789"],"is_preprint":false},{"year":2009,"finding":"Polyanions (dextran sulfate, heparin) bind C1s directly and exert a biphasic effect on its proteolytic activity (enhancement at low, inhibition at high concentrations). Polyanion-mediated acceleration of C1s–SERPING1 (C1 inhibitor) interaction requires both protease-polyanion and serpin-polyanion interactions.","method":"Kinetic inhibition assays, chimaeric alpha1-antitrypsin mutant unable to bind polyanions","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinetic assays with chimeric serpin control; single lab","pmids":["19522701"],"is_preprint":false},{"year":1986,"finding":"Intradermal injection of C1s in guinea pigs causes increased vascular permeability; this effect requires complement component C2, as C2-deficient guinea pigs fail to show permeability increase. C2-deficient animals respond normally to bradykinin and kallikrein. Reconstitution with guinea pig C2 restores C1s-induced permeability.","method":"In vivo intradermal injection, genetic complement-deficient animals, component reconstitution","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with reconstitution, establishes C2 requirement downstream of C1s","pmids":["3487577"],"is_preprint":false},{"year":2016,"finding":"Knockdown of C1s (and C1r) in cutaneous squamous cell carcinoma cells inhibited ERK1/2 and Akt activation, promoted apoptosis, and suppressed tumor growth and vascularization in xenograft models, demonstrating a tumor-cell-autonomous pro-survival signaling role for C1s.","method":"shRNA knockdown, Western blot for ERK/Akt, xenograft tumor growth assay","journal":"The British journal of dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific signaling readout and in vivo xenograft, but C1r and C1s were knocked down together, limiting attribution to C1s alone","pmids":["31049937"],"is_preprint":false},{"year":2016,"finding":"Two pEDS-associated C1S missense mutations (p.Val316del and p.Cys294Arg) cause local CCP1 module misfolding, exposing a cryptic cleavage site (Lys353-Cys354). Cells expressing mutant C1s secrete only a truncated Fg40 fragment (40 kDa) containing the intact SP domain but lacking the N-terminal interaction domains. Fg40 retains esterolytic activity and HMGB1-cleaving activity but has impaired C4 activation; it escapes physiological control within the C1 complex.","method":"Cell transfection, recombinant protein purification, mass spectrometry, N-terminal sequencing, enzymatic activity assays","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — two independent mutations studied with multiple orthogonal biochemical methods; rigorous functional characterization","pmids":["31921203"],"is_preprint":false},{"year":2019,"finding":"C1s (hamster/CHO-derived) is responsible for proteolysis of recombinant HIV gp120 in CHO cells at a specific serine-protease-sensitive epitope. CRISPR/Cas9 knockout of C1s in CHO cells eliminates this proteolytic clipping activity.","method":"CRISPR/Cas9 gene knockout, recombinant protein expression, Western blot analysis","journal":"Biotechnology and bioengineering","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with clear functional readout; single lab, substrate not a canonical C1s target","pmids":["31087560"],"is_preprint":false},{"year":1988,"finding":"The human C1r and C1s genes are located in a tail-to-tail arrangement on chromosome 12p13, approximately 9.5 kb apart. Both genes are primarily expressed in liver; C1s mRNA undergoes alternative polyadenylation generating multiple transcript sizes.","method":"Southern blot, genomic DNA sequencing, RNA blot analysis, in situ hybridization","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct genomic and expression analysis with multiple complementary methods","pmids":["2459702"],"is_preprint":false}],"current_model":"C1s is a modular serine protease that circulates as a zymogen within the Ca2+-dependent C1s-C1r-C1r-C1s tetramer (assembled via CUB1-EGF-CUB2 head-to-tail heterodimer interfaces) associated with C1q; upon C1q binding to antibody–antigen complexes or other activating surfaces, C1r undergoes autoactivation and cleaves C1s at Arg422-Ile423 to generate the two-chain active enzyme, which then uses exosites on its CCP1-CCP2 modules and four positively charged residues on its SP domain to recognize and cleave C4 (releasing C4a and C4b) and C2, propagating the classical complement cascade; C1s activity is tightly regulated by C1 inhibitor (SERPING1), which forms a 1:1 covalent SDS-stable complex with the C1s light chain and is cleared via LRP, while heparin/polyanions accelerate this inhibition; beyond complement substrates, C1s also cleaves IGFBP-5, beta2-microglobulin, HMGB1, and MMP-9 zymogen, and gain-of-function mutations in C1S associated with periodontal Ehlers-Danlos syndrome cause CCP1 misfolding that generates a truncated, unregulated SP fragment with altered substrate specificity."},"narrative":{"mechanistic_narrative":"C1S encodes a modular serine protease that serves as the catalytic effector of the classical complement pathway, circulating as a zymogen within the Ca2+-dependent C1s-C1r-C1r-C1s tetramer associated with C1q [PMID:23922389, PMID:29311313]. C1s is built from an N-terminal interaction region (two EGF-like and two CCP modules plus CUB domains) and a C-terminal trypsin-like serine protease domain [PMID:3500856], and its CUB1-EGF and CUB1-EGF-CUB2 interfaces drive Ca2+-dependent self-association and preferential C1r-C1s heterodimer formation that organizes the compact ring-shaped C1 complex and presents six C1q-binding sites, one per C1q collagen stem [PMID:12788922, PMID:29311313, PMID:19473974]. The protease's interaction sites for C1q and C1r reside entirely on the A chain, structurally independent of the catalytic B chain [PMID:2847785]. Within C1, surface-bound C1q triggers C1r autoactivation, which cleaves C1s to generate the two-chain active enzyme [PMID:869924]; activation repositions zymogen SP-domain loops that otherwise sterically block C4 binding [PMID:23592783]. Active C1s then propagates the cascade by cleaving C4 and C2 (generating C2a and C2b, the latter bearing the C4b-binding site) to assemble the C3 convertase [PMID:869924, PMID:70787]. Efficient C4 recognition depends on cooperating exosites — the CCP1-CCP2 junction and four positively charged SP-domain residues that engage sulfotyrosine residues on C4 — whereas C2 cleavage is governed by the SP domain alone [PMID:23592783, PMID:9422791, PMID:22855709, PMID:16227207], and intrinsic active-site specificity favors Arg/Lys at P1 [PMID:16169853]. C1s activity is controlled by C1 inhibitor (SERPING1), which forms a stable 1:1 covalent SDS-resistant complex with the C1s light chain following second-order kinetics that heparin and polyanions accelerate; the resulting complexes are cleared via LRP [PMID:123251, PMID:3091067, PMID:9388254, PMID:19522701]. Beyond complement, C1s cleaves non-canonical substrates including IGFBP-5, beta2-microglobulin, the alarmin HMGB1, and the zymogen of MMP-9, linking the protease to growth-factor signaling, inflammation, and matrix degradation [PMID:10982804, PMID:2110898, PMID:27648302, PMID:8082118]. Gain-of-function C1S mutations associated with periodontal Ehlers-Danlos syndrome cause CCP1 misfolding that exposes a cryptic cleavage site, yielding a truncated, unregulated SP fragment (Fg40) with retained esterolytic and HMGB1-cleaving activity but impaired C4 activation that escapes control within the C1 complex [PMID:31921203].","teleology":[{"year":1977,"claim":"Established that C1s is a two-chain trypsin-like serine protease with narrow specificity that is generated by C1r cleavage and acts on the complement substrates C4 and C2, defining its core enzymatic identity and cascade position.","evidence":"SDS-PAGE, N-terminal sequencing, and esterolytic/cleavage assays on purified C1s, plus C2 fragment characterization by electrophoresis and C4b-Sepharose binding","pmids":["869924","70787"],"confidence":"High","gaps":["Domain organization and structural basis of specificity not yet resolved","Mechanism of activation within the assembled C1 complex not addressed"]},{"year":1975,"claim":"Identified C1 inhibitor as the physiological regulator of C1s, forming a stable conformation-dependent 1:1 covalent complex via the C1s light chain — the founding observation of complement protease control.","evidence":"SDS-PAGE, size-exclusion chromatography, and activity assays with acid-denaturation controls","pmids":["123251"],"confidence":"High","gaps":["Kinetics and rate of inhibition not quantified","In vivo fate of the inhibited complex unknown"]},{"year":1987,"claim":"Determined the complete primary sequence and modular domain architecture of C1s (EGF, CCP, and SP domains), providing the framework for mapping interaction versus catalytic functions.","evidence":"cDNA cloning and nucleotide sequencing from a human liver library with amino acid sequence validation","pmids":["3500856"],"confidence":"High","gaps":["Functional contribution of individual domains not yet dissected","Three-dimensional structure unresolved"]},{"year":1988,"claim":"Localized all C1q- and C1r-binding capacity to the A chain and showed the catalytic B chain is structurally independent, separating assembly functions from proteolysis; also mapped the C1r/C1s gene pair to chromosome 12p13 with liver-predominant expression.","evidence":"Limited proteolysis, exclusion chromatography, hemolytic reconstitution; genomic Southern/RNA blot and in situ hybridization","pmids":["2847785","2459702"],"confidence":"High","gaps":["Atomic details of the interaction interfaces not yet defined","Regulation of tissue-specific expression not addressed"]},{"year":1992,"claim":"Quantified Ca2+-dependent C1s self-association and showed that catalytic post-translational modifications (beta-hydroxylation, sialylation, one N-glycan) are dispensable for C1 assembly and activation, clarifying which features are essential for function.","evidence":"Sedimentation equilibrium ultracentrifugation; baculovirus expression with site-directed mutagenesis and hemolytic assays","pmids":["1445906","1533159"],"confidence":"High","gaps":["Structural basis of the high-affinity interfacial Ca2+ site not resolved","Role of glycans in stability/secretion not examined"]},{"year":1998,"claim":"Demonstrated that both CCP modules are required for efficient C4 cleavage (~70-fold loss without CCP1) while C2 cleavage is CCP-independent, establishing that the CCP modules carry C4-specific substrate-recognition exosites.","evidence":"Baculovirus expression of truncated recombinant C1s with quantitative cleavage assays","pmids":["9422791"],"confidence":"High","gaps":["Molecular nature of the CCP exosite contacts not defined","Generalizability to other substrates untested"]},{"year":2003,"claim":"Solved the CUB1-EGF structure showing a Ca2+-stabilized head-to-tail homodimer and a novel Ca2+-binding CUB module, providing the structural basis for Ca2+-dependent C1r-C1s association and C1q binding.","evidence":"X-ray crystallography at 1.5 Å with Ca2+ coordination analysis","pmids":["12788922"],"confidence":"High","gaps":["Heterodimer (vs homodimer) interface not yet captured","Arrangement within the intact tetramer unresolved"]},{"year":2005,"claim":"Mapped active-site specificity (P1 Arg/Lys dominant) and used C1s/MASP-2 chimeras to localize C4-cleavage efficiency to the CCP modules and C2-cleavage efficiency to the SP domain, partitioning substrate selectivity across the molecule.","evidence":"Randomized phage display library with kinetics; baculovirus chimeric proteins with kinetic cleavage assays and C1 reconstitution","pmids":["16169853","16227207"],"confidence":"High","gaps":["Atomic contacts of the CCP-mediated C4 exosite not yet visualized","Determinants of non-complement substrate selection not addressed"]},{"year":2012,"claim":"Identified four positively charged SP-domain residues forming a catalytic exosite that engages sulfotyrosines on C4, providing the molecular basis for high-efficiency C4 recognition beyond the active site.","evidence":"Site-directed mutagenesis, crystallographic sulfate coordination, and peptide binding assays","pmids":["22855709"],"confidence":"High","gaps":["Coordination of SP exosite with CCP exosite during catalysis not fully integrated","Contribution to C2 cleavage not defined"]},{"year":2013,"claim":"Defined the structural logic of zymogen-to-active transition and the architecture of C1: zymogen SP loops sterically block C4 binding until activation, and C1q stems contact CUB-module lysines/acidic residues to organize the compact head-to-tail tetramer poised for activation.","evidence":"X-ray crystallography of zymogen CCP1-CCP2-SP and of C1s–collagen/tetramer complexes, with SPR and mutagenesis validation","pmids":["23592783","23922389"],"confidence":"High","gaps":["Dynamic conformational steps of in-situ activation not directly observed","How surface binding mechanically triggers C1r remained partly inferred"]},{"year":2018,"claim":"Resolved the C1r-C1s CUB1-EGF-CUB2 heterodimer as an antiparallel L-shaped, Ca2+-bridged assembly with more extensive contacts than homodimers, explaining preferential heterocomplex formation and proposing activation by separation of dimer pairs upon C1q surface binding.","evidence":"X-ray crystallography and biophysical analysis","pmids":["29311313"],"confidence":"High","gaps":["Direct visualization of the activation conformational change in intact C1 not achieved","Kinetics of the dimer-separation step not measured"]},{"year":1997,"claim":"Established that C1-inhibitor·C1s complexes are catabolized via the LRP receptor, defining the clearance route for spent protease-inhibitor complexes.","evidence":"Cell binding assays, in vivo clearance with RAP inhibition, and LRP-deficient fibroblasts","pmids":["9388254"],"confidence":"High","gaps":["LRP-binding determinants on the complex not mapped","Quantitative contribution relative to other clearance routes unknown"]},{"year":1986,"claim":"Quantified C1 inhibitor as a covalent second-order inactivator of C1s and showed heparin accelerates inhibition up to 35-fold, defining a tunable regulatory mechanism later extended to other polyanions.","evidence":"Esterolytic kinetics, HPLC size-exclusion, fluorescence probes; later kinetic assays with a polyanion-binding-deficient chimeric serpin","pmids":["3091067","19522701"],"confidence":"High","gaps":["Physiological polyanion(s) modulating C1s in vivo not identified","Biphasic concentration dependence mechanism only partly explained"]},{"year":1998,"claim":"Showed anti-C1-inhibitor autoantibodies convert C1 inhibitor into a cleavable substrate that fails to form a stable covalent complex, defining an acquired mechanism of dysregulated C1s activity.","evidence":"SDS-PAGE complex analysis, esterolytic assays, and peptide competition mapping","pmids":["9508789"],"confidence":"Medium","gaps":["Single-lab finding without independent replication","In vivo relevance to specific patient phenotypes not established"]},{"year":2000,"claim":"Extended C1s function beyond complement by identifying it as the fibroblast protease that selectively cleaves IGFBP-5, linking C1s to growth-factor bioavailability under C1-inhibitor control.","evidence":"Protein purification, sequencing, IGFBP-5 zymography, C4 cleavage and C1-inhibitor inhibition assays","pmids":["10982804"],"confidence":"High","gaps":["Physiological/in vivo significance of IGFBP-5 cleavage not established","Selectivity determinants for IGFBP-5 over IGFBP-1–4 not defined"]},{"year":1990,"claim":"Identified beta2-microglobulin (cleaved at Lys-58) as the first non-complement protein substrate of C1s, broadening the recognized substrate repertoire.","evidence":"In vitro protease assay with product sequencing and C1 esterase inhibitor control","pmids":["2110898"],"confidence":"High","gaps":["Biological consequence of beta2-microglobulin cleavage not determined","In vivo occurrence not demonstrated"]},{"year":2016,"claim":"Showed that C1s, both purified and within the C1 complex, cleaves the alarmin HMGB1 into defined fragments that lose pro-inflammatory cytokine-enhancing activity, and identified additional intracellular substrates, implicating C1s in modulating inflammation during apoptotic-cell handling.","evidence":"In vitro protease assays, mass spectrometry, and monocyte/macrophage/DC cytokine production assays","pmids":["27648302"],"confidence":"High","gaps":["In vivo contribution to inflammation resolution not established","Functional impact of the additional intracellular substrates not characterized"]},{"year":2016,"claim":"Provided the molecular basis of periodontal Ehlers-Danlos syndrome by showing pEDS C1S mutations misfold CCP1, exposing a cryptic cleavage site that yields a truncated, regulation-escaping SP fragment with altered substrate behavior.","evidence":"Cell transfection, recombinant purification, mass spectrometry, N-terminal sequencing, and enzymatic assays on two independent mutants","pmids":["31921203"],"confidence":"High","gaps":["In vivo substrate spectrum and tissue consequences of Fg40 not defined","Link between altered proteolysis and connective-tissue pathology mechanistically incomplete"]},{"year":1994,"claim":"Reported that C1s activates the MMP-9 zymogen, proposing a role in cartilage matrix degradation alongside complement-independent proteolysis.","evidence":"Immunohistochemistry and in vitro zymogen activation assay","pmids":["8082118"],"confidence":"Medium","gaps":["Single in vitro activation assay with limited functional follow-up","In vivo relevance to matrix turnover not demonstrated"]},{"year":2016,"claim":"Implicated C1s in tumor-cell-autonomous pro-survival signaling, where knockdown reduced ERK/Akt activation, increased apoptosis, and suppressed xenograft tumor growth.","evidence":"shRNA knockdown, Western blot for ERK/Akt, and xenograft assays in cutaneous SCC cells","pmids":["31049937"],"confidence":"Medium","gaps":["C1r and C1s knocked down together, limiting attribution to C1s alone","Molecular link between C1s proteolysis and ERK/Akt signaling undefined"]},{"year":null,"claim":"It remains unresolved how C1s's non-complement substrate cleavages (IGFBP-5, beta2-microglobulin, HMGB1, MMP-9) and its tumor pro-survival signaling role operate in vivo, and how substrate selection is governed outside the canonical C4/C2 exosite framework.","evidence":"No direct in vivo mechanistic study in the timeline integrates these activities","pmids":[],"confidence":"Low","gaps":["No in vivo demonstration of physiological non-complement substrate cleavage","Signaling mechanism downstream of C1s in tumor cells unmapped","Substrate-recognition rules for non-complement targets undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,9,10,11,13,14,15,20,30]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13,25,32]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,7,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[9,13,14,15,20]}],"complexes":["C1 complex (C1q-C1r2-C1s2)","C1s-C1r-C1r-C1s tetramer","C1s–C1 inhibitor (SERPING1) covalent complex"],"partners":["C1R","C1QA","C4","C2","SERPING1","LRP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09871","full_name":"Complement C1s subcomponent","aliases":["C1 esterase","Complement component 1 subcomponent s"],"length_aa":688,"mass_kda":76.7,"function":"Component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:11445589, PubMed:16169853, PubMed:417728, PubMed:467643, PubMed:6271784, PubMed:6282646, PubMed:6319179, PubMed:70787, PubMed:9422791). C1S is activated following association of the C1 complex with immunoglobulins (IgG or IgM) complexed with antigens to form antigen-antibody complexes on the surface of pathogens (PubMed:34155115). C1S is cleaved and activated by C1R to generate C1s subcomponent heavy and light chains (PubMed:11445589, PubMed:6271784). C1s subcomponent light chain then cleaves and activates C2 and C4, the next components of the classical complement pathway (PubMed:16169853, PubMed:467643, PubMed:6282646, PubMed:6319179, PubMed:6906228, PubMed:70787, PubMed:9422791) Serine protease component of the complement C1 complex, which catalyzes cleavage and activation of C2 and C4, the next components of the classical complement pathway (PubMed:16169853, PubMed:22949645, PubMed:417728, PubMed:467643, PubMed:6282646, PubMed:6319179, PubMed:70787, PubMed:9422791). Also able to cleave C1 inhibitor (SERPING1) in vitro; additional evidence is however required to confirm this result in vivo (PubMed:16169853). Also cleaves IGFBP5 and thereby inhibits the trophic effects of IGF1 (PubMed:18930415)","subcellular_location":"Secreted; Cell surface","url":"https://www.uniprot.org/uniprotkb/P09871/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/C1S","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/C1S","total_profiled":1310},"omim":[{"mim_id":"617174","title":"EHLERS-DANLOS SYNDROME, PERIODONTAL TYPE, 2; EDSPD2","url":"https://www.omim.org/entry/617174"},{"mim_id":"613785","title":"COMPLEMENT COMPONENT 1, r SUBCOMPONENT; C1R","url":"https://www.omim.org/entry/613785"},{"mim_id":"613783","title":"COMPLEMENT COMPONENT C1s DEFICIENCY; C1SD","url":"https://www.omim.org/entry/613783"},{"mim_id":"609862","title":"TRANSMEMBRANE PROTEASE, SERINE 6; TMPRSS6","url":"https://www.omim.org/entry/609862"},{"mim_id":"609342","title":"COBALAMIN-BINDING INTRINSIC FACTOR; CBLIF","url":"https://www.omim.org/entry/609342"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":2663.1}],"url":"https://www.proteinatlas.org/search/C1S"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P09871","domains":[{"cath_id":"2.60.120.290","chopping":"21-133","consensus_level":"high","plddt":91.4317,"start":21,"end":133},{"cath_id":"2.10.25.10","chopping":"137-172","consensus_level":"medium","plddt":81.8661,"start":137,"end":172},{"cath_id":"2.60.120.290","chopping":"176-292","consensus_level":"medium","plddt":93.102,"start":176,"end":292},{"cath_id":"2.10.70.10","chopping":"294-357","consensus_level":"medium","plddt":89.208,"start":294,"end":357},{"cath_id":"2.10.70.10","chopping":"369-423","consensus_level":"high","plddt":90.5131,"start":369,"end":423},{"cath_id":"2.40.10.10","chopping":"443-681","consensus_level":"medium","plddt":87.532,"start":443,"end":681}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09871","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09871-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09871-F1-predicted_aligned_error_v6.png","plddt_mean":87.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=C1S","jax_strain_url":"https://www.jax.org/strain/search?query=C1S"},"sequence":{"accession":"P09871","fasta_url":"https://rest.uniprot.org/uniprotkb/P09871.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09871/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09871"}},"corpus_meta":[{"pmid":"1460414","id":"PMC_1460414","title":"Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1460414","citation_count":509,"is_preprint":false},{"pmid":"123251","id":"PMC_123251","title":"Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.","date":"1975","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/123251","citation_count":228,"is_preprint":false},{"pmid":"869924","id":"PMC_869924","title":"The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement.","date":"1977","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/869924","citation_count":141,"is_preprint":false},{"pmid":"6318736","id":"PMC_6318736","title":"Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes.","date":"1983","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/6318736","citation_count":130,"is_preprint":false},{"pmid":"70787","id":"PMC_70787","title":"Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.","date":"1977","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/70787","citation_count":124,"is_preprint":false},{"pmid":"24695853","id":"PMC_24695853","title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24695853","citation_count":122,"is_preprint":false},{"pmid":"2917186","id":"PMC_2917186","title":"Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass.","date":"1989","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/2917186","citation_count":118,"is_preprint":false},{"pmid":"10775260","id":"PMC_10775260","title":"Crystal structure of the catalytic domain of human complement c1s: a serine protease with a handle.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10775260","citation_count":92,"is_preprint":false},{"pmid":"10878362","id":"PMC_10878362","title":"Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10878362","citation_count":89,"is_preprint":false},{"pmid":"3500856","id":"PMC_3500856","title":"Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence.","date":"1987","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3500856","citation_count":87,"is_preprint":false},{"pmid":"8912663","id":"PMC_8912663","title":"Improvements on the purification of mannan-binding lectin and demonstration of its Ca(2+)-independent association with a C1s-like serine protease.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8912663","citation_count":83,"is_preprint":false},{"pmid":"23922389","id":"PMC_23922389","title":"Structural basis of the C1q/C1s interaction and its central role in assembly of the C1 complex of complement activation.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23922389","citation_count":80,"is_preprint":false},{"pmid":"27745832","id":"PMC_27745832","title":"Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27745832","citation_count":79,"is_preprint":false},{"pmid":"8416956","id":"PMC_8416956","title":"Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8416956","citation_count":76,"is_preprint":false},{"pmid":"31049937","id":"PMC_31049937","title":"Tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma.","date":"2019","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31049937","citation_count":73,"is_preprint":false},{"pmid":"28980446","id":"PMC_28980446","title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.","date":"2017","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/28980446","citation_count":73,"is_preprint":false},{"pmid":"10982804","id":"PMC_10982804","title":"The complement component C1s is the protease that accounts for cleavage of insulin-like growth factor-binding protein-5 in fibroblast medium.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10982804","citation_count":70,"is_preprint":false},{"pmid":"12788922","id":"PMC_12788922","title":"X-ray structure of the Ca2+-binding interaction domain of C1s. Insights into the assembly of the C1 complex of complement.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12788922","citation_count":70,"is_preprint":false},{"pmid":"19473974","id":"PMC_19473974","title":"Identification of the C1q-binding Sites of Human C1r and C1s: a refined three-dimensional model of the C1 complex of complement.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19473974","citation_count":66,"is_preprint":false},{"pmid":"15210793","id":"PMC_15210793","title":"Structural and functional characterization of complement C4 and C1s-like molecules in teleost fish: insights into the evolution of classical and alternative pathways.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15210793","citation_count":65,"is_preprint":false},{"pmid":"11673555","id":"PMC_11673555","title":"Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11673555","citation_count":63,"is_preprint":false},{"pmid":"15364579","id":"PMC_15364579","title":"The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15364579","citation_count":62,"is_preprint":false},{"pmid":"2459702","id":"PMC_2459702","title":"Human genes for complement components C1r and C1s in a close tail-to-tail arrangement.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2459702","citation_count":60,"is_preprint":false},{"pmid":"29311313","id":"PMC_29311313","title":"Structure of the C1r-C1s interaction of the C1 complex of complement activation.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29311313","citation_count":58,"is_preprint":false},{"pmid":"9422791","id":"PMC_9422791","title":"Baculovirus-mediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s. Evidence for the involvement of both complement control protein modules in the recognition of the C4 protein substrate.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9422791","citation_count":58,"is_preprint":false},{"pmid":"19477526","id":"PMC_19477526","title":"Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19477526","citation_count":56,"is_preprint":false},{"pmid":"8240317","id":"PMC_8240317","title":"A new member of the C1s family of complement proteins found in a bactericidal factor, Ra-reactive factor, in human serum.","date":"1993","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8240317","citation_count":53,"is_preprint":false},{"pmid":"23650384","id":"PMC_23650384","title":"Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sites.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23650384","citation_count":51,"is_preprint":false},{"pmid":"10364916","id":"PMC_10364916","title":"Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody.","date":"1999","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/10364916","citation_count":48,"is_preprint":false},{"pmid":"2110898","id":"PMC_2110898","title":"Limited proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s.","date":"1990","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2110898","citation_count":48,"is_preprint":false},{"pmid":"2026272","id":"PMC_2026272","title":"Complement components C1r/C1s, bone morphogenic protein 1 and Xenopus laevis developmentally regulated protein UVS.2 share common repeats.","date":"1991","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/2026272","citation_count":45,"is_preprint":false},{"pmid":"9420617","id":"PMC_9420617","title":"A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s.","date":"1997","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9420617","citation_count":44,"is_preprint":false},{"pmid":"11390518","id":"PMC_11390518","title":"Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11390518","citation_count":44,"is_preprint":false},{"pmid":"3091067","id":"PMC_3091067","title":"Kinetics of interaction of C1 inhibitor with complement C1s.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3091067","citation_count":44,"is_preprint":false},{"pmid":"8082118","id":"PMC_8082118","title":"Immunolocalization of complement C1s and matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase) in the primary ossification center of the human femur.","date":"1994","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/8082118","citation_count":43,"is_preprint":false},{"pmid":"2553984","id":"PMC_2553984","title":"Complement genes C1r and C1s feature an intronless serine protease domain closely related to haptoglobin.","date":"1989","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2553984","citation_count":41,"is_preprint":false},{"pmid":"108204","id":"PMC_108204","title":"Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2.","date":"1979","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/108204","citation_count":40,"is_preprint":false},{"pmid":"8133044","id":"PMC_8133044","title":"A 100-kDa protein in the C4-activating component of Ra-reactive factor is a new serine protease having module organization similar to C1r and C1s.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8133044","citation_count":39,"is_preprint":false},{"pmid":"9388254","id":"PMC_9388254","title":"C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9388254","citation_count":37,"is_preprint":false},{"pmid":"18062908","id":"PMC_18062908","title":"Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene.","date":"2007","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18062908","citation_count":37,"is_preprint":false},{"pmid":"20008834","id":"PMC_20008834","title":"Analysis of human C1q by combined bottom-up and top-down mass spectrometry: detailed mapping of post-translational modifications and insights into the C1r/C1s binding sites.","date":"2009","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/20008834","citation_count":37,"is_preprint":false},{"pmid":"7779774","id":"PMC_7779774","title":"Structure of the catalytic region of human complement protease C1s: study by chemical cross-linking and three-dimensional homology modeling.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7779774","citation_count":37,"is_preprint":false},{"pmid":"16169853","id":"PMC_16169853","title":"Elucidation of the substrate specificity of the C1s protease of the classical complement pathway.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169853","citation_count":36,"is_preprint":false},{"pmid":"25904443","id":"PMC_25904443","title":"An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA.","date":"2015","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/25904443","citation_count":35,"is_preprint":false},{"pmid":"16227207","id":"PMC_16227207","title":"Functional characterization of complement proteases C1s/mannan-binding lectin-associated serine protease-2 (MASP-2) chimeras reveals the higher C4 recognition efficacy of the MASP-2 complement control protein modules.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16227207","citation_count":33,"is_preprint":false},{"pmid":"6604603","id":"PMC_6604603","title":"C1 inactivator-C1s complexes in inflammatory joint disease.","date":"1983","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/6604603","citation_count":32,"is_preprint":false},{"pmid":"2847785","id":"PMC_2847785","title":"Domain structure, stability, and interactions of human complement C1s-: characterization of a derivative lacking most of the B chain.","date":"1988","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2847785","citation_count":32,"is_preprint":false},{"pmid":"2834284","id":"PMC_2834284","title":"Assignment of the complement serine protease genes C1r and C1s to chromosome 12 region 12p13.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2834284","citation_count":30,"is_preprint":false},{"pmid":"36275687","id":"PMC_36275687","title":"Complement C1s as a diagnostic marker and therapeutic target: Progress and propective.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36275687","citation_count":29,"is_preprint":false},{"pmid":"26769276","id":"PMC_26769276","title":"Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity.","date":"2016","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/26769276","citation_count":29,"is_preprint":false},{"pmid":"1533159","id":"PMC_1533159","title":"Recombinant human complement subcomponent C1s lacking beta-hydroxyasparagine, sialic acid, and one of its two carbohydrate chains still reassembles with C1q and C1r to form a functional C1 complex.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1533159","citation_count":29,"is_preprint":false},{"pmid":"7718002","id":"PMC_7718002","title":"Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures.","date":"1995","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/7718002","citation_count":28,"is_preprint":false},{"pmid":"3029222","id":"PMC_3029222","title":"Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.","date":"1987","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3029222","citation_count":28,"is_preprint":false},{"pmid":"36420270","id":"PMC_36420270","title":"Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36420270","citation_count":27,"is_preprint":false},{"pmid":"32176765","id":"PMC_32176765","title":"Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32176765","citation_count":27,"is_preprint":false},{"pmid":"1445906","id":"PMC_1445906","title":"Calcium-linked self-association of human complement C1s.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1445906","citation_count":26,"is_preprint":false},{"pmid":"28926521","id":"PMC_28926521","title":"Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.","date":"2017","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/28926521","citation_count":26,"is_preprint":false},{"pmid":"23592783","id":"PMC_23592783","title":"A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23592783","citation_count":25,"is_preprint":false},{"pmid":"11220628","id":"PMC_11220628","title":"Molecular cloning of the complement (C1r/C1s/MASP2-like serine proteases from the common carp (Cyprinus carpio).","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11220628","citation_count":25,"is_preprint":false},{"pmid":"8921412","id":"PMC_8921412","title":"Exon structure of the gene encoding the human mannose-binding protein-associated serine protease light chain: comparison with complement C1r and C1s genes.","date":"1996","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8921412","citation_count":25,"is_preprint":false},{"pmid":"22855709","id":"PMC_22855709","title":"Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22855709","citation_count":25,"is_preprint":false},{"pmid":"6602754","id":"PMC_6602754","title":"Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.","date":"1983","source":"Hoppe-Seyler's Zeitschrift fur physiologische Chemie","url":"https://pubmed.ncbi.nlm.nih.gov/6602754","citation_count":25,"is_preprint":false},{"pmid":"31087560","id":"PMC_31087560","title":"Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.","date":"2019","source":"Biotechnology and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/31087560","citation_count":24,"is_preprint":false},{"pmid":"30635392","id":"PMC_30635392","title":"C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30635392","citation_count":24,"is_preprint":false},{"pmid":"3487577","id":"PMC_3487577","title":"C1s-induced vascular permeability in C2-deficient guinea pigs.","date":"1986","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3487577","citation_count":24,"is_preprint":false},{"pmid":"3492208","id":"PMC_3492208","title":"Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus.","date":"1986","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/3492208","citation_count":23,"is_preprint":false},{"pmid":"7011949","id":"PMC_7011949","title":"Immunofluorescence studies on the subcomponents of the first component of complement (C1): detection of C1q and C1s in different cells of biopsy material and on human as well as on guinea pig peritoneal macrophages.","date":"1981","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/7011949","citation_count":23,"is_preprint":false},{"pmid":"3876244","id":"PMC_3876244","title":"Characterization of C1q, C1s and C-1 Inh synthesized by stimulated human monocytes in vitro.","date":"1985","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/3876244","citation_count":23,"is_preprint":false},{"pmid":"3099750","id":"PMC_3099750","title":"Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.","date":"1986","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/3099750","citation_count":22,"is_preprint":false},{"pmid":"37119056","id":"PMC_37119056","title":"An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy.","date":"2023","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/37119056","citation_count":21,"is_preprint":false},{"pmid":"10408360","id":"PMC_10408360","title":"Structure and functions of the interaction domains of C1r and C1s: keystones of the architecture of the C1 complex.","date":"1999","source":"Immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10408360","citation_count":21,"is_preprint":false},{"pmid":"9856483","id":"PMC_9856483","title":"Selective complement C1s deficiency caused by homozygous four-base deletion in the C1s gene.","date":"1998","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9856483","citation_count":21,"is_preprint":false},{"pmid":"6149574","id":"PMC_6149574","title":"Structure and activity of C1r and C1s.","date":"1984","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/6149574","citation_count":21,"is_preprint":false},{"pmid":"1898597","id":"PMC_1898597","title":"Biochemical characterization and tissue distribution of hamster complement C1s.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1898597","citation_count":21,"is_preprint":false},{"pmid":"9508789","id":"PMC_9508789","title":"Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.","date":"1998","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/9508789","citation_count":21,"is_preprint":false},{"pmid":"27648302","id":"PMC_27648302","title":"Proteolytic inactivation of nuclear alarmin high-mobility group box 1 by complement protease C1s during apoptosis.","date":"2016","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27648302","citation_count":21,"is_preprint":false},{"pmid":"3874014","id":"PMC_3874014","title":"Determination of C1s-C1 inhibitor complexes in plasma by means of an enzyme linked immunosorbent assay.","date":"1985","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3874014","citation_count":21,"is_preprint":false},{"pmid":"28882800","id":"PMC_28882800","title":"C1r and C1s from Nile tilapia (Oreochromis niloticus): Molecular characterization, transcriptional profiling upon bacterial and IFN-γ inductions and potential role in response to bacterial infection.","date":"2017","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28882800","citation_count":20,"is_preprint":false},{"pmid":"3874650","id":"PMC_3874650","title":"Changes in protein conformation and stability accompany complex formation between human C1 inhibitor and C1-s.","date":"1985","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3874650","citation_count":20,"is_preprint":false},{"pmid":"23271740","id":"PMC_23271740","title":"Zebrafish scube1 (signal peptide-CUB (complement protein C1r/C1s, Uegf, and Bmp1)-EGF (epidermal growth factor) domain-containing protein 1) is involved in primitive hematopoiesis.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23271740","citation_count":19,"is_preprint":false},{"pmid":"37246953","id":"PMC_37246953","title":"Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.","date":"2023","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/37246953","citation_count":19,"is_preprint":false},{"pmid":"20592021","id":"PMC_20592021","title":"Mapping surface accessibility of the C1r/C1s tetramer by chemical modification and mass spectrometry provides new insights into assembly of the human C1 complex.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20592021","citation_count":19,"is_preprint":false},{"pmid":"24218249","id":"PMC_24218249","title":"Classical complement pathway components C1r and C1s: purification from human serum and in recombinant form and functional characterization.","date":"2014","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24218249","citation_count":18,"is_preprint":false},{"pmid":"12513694","id":"PMC_12513694","title":"Complement C1r and C1s genes are duplicated in the mouse: differential expression generates alternative isomorphs in the liver and in the male reproductive system.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12513694","citation_count":18,"is_preprint":false},{"pmid":"38085846","id":"PMC_38085846","title":"Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38085846","citation_count":18,"is_preprint":false},{"pmid":"28251805","id":"PMC_28251805","title":"Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.","date":"2017","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/28251805","citation_count":18,"is_preprint":false},{"pmid":"1575792","id":"PMC_1575792","title":"Selective deficiency of C1s associated with a systemic lupus erythematosus-like syndrome. Report of a case.","date":"1992","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/1575792","citation_count":18,"is_preprint":false},{"pmid":"12192078","id":"PMC_12192078","title":"alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.","date":"2002","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/12192078","citation_count":17,"is_preprint":false},{"pmid":"8144914","id":"PMC_8144914","title":"Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8144914","citation_count":17,"is_preprint":false},{"pmid":"12356684","id":"PMC_12356684","title":"Functional characterization of human mannose-binding lectin-associated serine protease (MASP)-1/3 and MASP-2 promoters, and comparison with the C1s promoter.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12356684","citation_count":16,"is_preprint":false},{"pmid":"12396001","id":"PMC_12396001","title":"C1s, the protease messenger of C1. Structure, function and physiological significance.","date":"2002","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/12396001","citation_count":15,"is_preprint":false},{"pmid":"9683269","id":"PMC_9683269","title":"Expression and characterization of a 159 amino acid, N-terminal fragment of human complement component C1s.","date":"1997","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9683269","citation_count":15,"is_preprint":false},{"pmid":"8766156","id":"PMC_8766156","title":"Change of complement C1s synthesis during development of hamster cartilage.","date":"1996","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/8766156","citation_count":15,"is_preprint":false},{"pmid":"26241508","id":"PMC_26241508","title":"Characterization of rock bream (Oplegnathus fasciatus) complement components C1r and C1s in terms of molecular aspects, genomic modulation, and immune responsive transcriptional profiles following bacterial and viral pathogen exposure.","date":"2015","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26241508","citation_count":15,"is_preprint":false},{"pmid":"3019707","id":"PMC_3019707","title":"Biosynthesis of the subcomponents C1q, C1r and C1s of the first component of complement (C1) by guinea pig hepatocyte primary cultures.","date":"1986","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3019707","citation_count":15,"is_preprint":false},{"pmid":"31921203","id":"PMC_31921203","title":"Two Different Missense C1S Mutations, Associated to Periodontal Ehlers-Danlos Syndrome, Lead to Identical Molecular Outcomes.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31921203","citation_count":14,"is_preprint":false},{"pmid":"9524231","id":"PMC_9524231","title":"Molecular cloning of a cDNA encoding a serine protease homologous to complement C1s precursor from rat C6 glial cells and its expression during glial differentiation.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9524231","citation_count":14,"is_preprint":false},{"pmid":"15149641","id":"PMC_15149641","title":"A novel series of potent and selective small molecule inhibitors of the complement component C1s.","date":"2004","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/15149641","citation_count":14,"is_preprint":false},{"pmid":"19522701","id":"PMC_19522701","title":"Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19522701","citation_count":13,"is_preprint":false},{"pmid":"9211832","id":"PMC_9211832","title":"Coordinated change between complement C1s production and chondrocyte differentiation in vitro.","date":"1997","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/9211832","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49620,"output_tokens":7796,"usd":0.1329,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17181,"output_tokens":6232,"usd":0.120853,"stage2_stop_reason":"end_turn"},"total_usd":0.253753,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1977,\n      \"finding\": \"Activated C1s (C̄1s) consists of two polypeptide chains of ~56 kDa ('a' chain) and ~27 kDa ('b' chain); the 'b' chain bears the serine protease domain with trypsin-like homology. C1s hydrolyzes lysine ester bonds and cleaves C1s substrate C4 but does not cleave amino acid esters nor protein substrates other than those in the complement cascade, demonstrating its narrow specificity. Activated C1r cleaves C1s to generate the two-chain active form.\",\n      \"method\": \"SDS-PAGE, amino acid sequencing, N-terminal sequence analysis, esterolytic activity assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic characterization with sequencing, replicated across multiple labs over decades\",\n      \"pmids\": [\"869924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1977,\n      \"finding\": \"C1s cleaves C2 into two antigenically distinct fragments: C2a (73 kDa, larger, more acidic) and C2b (34 kDa, smaller, more basic). C2b contains the C4b-binding site and remains associated with C4b after C2a decay-release from the C3 convertase.\",\n      \"method\": \"In vitro cleavage assay, disc electrophoresis, immunoelectrophoresis, C4b-Sepharose binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with solid-phase binding assay, foundational biochemical study\",\n      \"pmids\": [\"70787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"C1 inhibitor forms a stable 1:1 molar SDS/urea-resistant complex with C1s via the light chain of C1s. Complex formation requires native (non-denatured) C1 inhibitor conformation. Plasmin degrades C1 inhibitor but at least one derivative retains the ability to complex C1s.\",\n      \"method\": \"SDS-PAGE, size-exclusion chromatography, enzyme activity assays, acid denaturation controls\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro biochemical reconstitution with multiple orthogonal methods; foundational mechanism paper\",\n      \"pmids\": [\"123251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structure of the C1s catalytic fragment (CCP2 + serine protease domain) resolved to 1.7 Å. The SP domain shows restricted access to subsidiary substrate binding sites, explaining narrow specificity. The CCP2 module is oriented perpendicularly to the SP domain surface via a rigid interface involving proline- and tyrosine-rich segments, and CCP2 provides additional substrate recognition sites for C4.\",\n      \"method\": \"X-ray crystallography at 1.7 Å resolution\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with functional interpretation; single rigorous paper\",\n      \"pmids\": [\"10775260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The complete amino acid sequence of human C1s (673 residues + 15-residue leader) was determined from cDNA. The N-terminal chain (422 residues) contains five domains including two EGF-like repeats, two CCP modules, and domains homologous to C1r. The C-terminal chain (251 residues) is the serine protease domain.\",\n      \"method\": \"cDNA cloning and nucleotide sequencing from human liver library, supported by amino acid sequence data\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complete sequence determination with independent amino acid sequence validation\",\n      \"pmids\": [\"3500856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structure of the C1s CUB1-EGF interaction domain resolved to 1.5 Å reveals a head-to-tail homodimer; Ca2+ is bound to the EGF module stabilizing intra- and inter-monomer interfaces. A second Ca2+ is bound to the CUB1 module via Glu45, Asp53, Asp98, defining a novel Ca2+-binding CUB module subset. This domain mediates Ca2+-dependent C1r-C1s association and C1q interaction.\",\n      \"method\": \"X-ray crystallography at 1.5 Å, Ca2+ coordination analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with detailed mechanistic interpretation of Ca2+ binding and protein-protein interaction\",\n      \"pmids\": [\"12788922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of a zymogen C1s construct (CCP1-CCP2-SP) reveals that two loops (492–499 and 573–580) in the zymogen SP domain adopt a conformation that sterically abrogates C4 binding. Activation repositions these loops to interact with sulfotyrosine residues on C4. SPR confirmed that only active C1s (not zymogen) binds C4. The CCP1-CCP2 junction constitutes an exosite for C4 recognition.\",\n      \"method\": \"X-ray crystallography, surface plasmon resonance (SPR)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with SPR binding assay, two orthogonal methods in one rigorous study\",\n      \"pmids\": [\"23592783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"C1q collagen-like stems bind C1s (and C1r) via a Ca2+-dependent mechanism involving a lysine side chain (critical residues LysB61 and LysC58 of C1q contacting acidic Ca2+-coordinating residues in C1r/C1s CUB modules). In C1, C1s forms a compact ring-shaped tetramer with a unique head-to-tail interaction at its center, enabling activation by C1r and access to substrates C4 and C2.\",\n      \"method\": \"X-ray crystallography (C1s–collagen peptide complex; C1s tetramer), SPR mutagenesis validation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures plus SPR mutagenesis, comprehensive structural characterization\",\n      \"pmids\": [\"23922389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of the C1r-C1s CUB1-EGF-CUB2 heterodimer reveals an antiparallel L-shaped arrangement with Ca2+ at the interface from each subcomponent. Contacts involve all three domains of each protease and are more extensive than homodimers, explaining preferential heterocomplex formation. In C1, two C1r-C1s dimers are linked via the C1r catalytic domains; activation is driven by separation of the dimer pairs upon C1q surface binding.\",\n      \"method\": \"X-ray crystallography, biophysical analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure of the C1r-C1s heterodimer with functional model, single rigorous paper\",\n      \"pmids\": [\"29311313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Both CCP modules of C1s are required for efficient C4 cleavage: deletion of CCP1 reduces C4-cleaving activity ~70-fold and deletion of both CCP modules abolishes it. C2 cleavage is minimally affected by CCP deletion. The carbohydrate moiety on CCP2 has no significant effect on catalytic activity.\",\n      \"method\": \"Baculovirus expression of truncated recombinant C1s fragments, functional cleavage assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted recombinant domain-deletion analysis with quantitative substrate cleavage assays\",\n      \"pmids\": [\"9422791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Phage display randomized library profiling revealed that C1s substrate specificity is determined primarily by the P1 position (Arg/Lys), followed by P3 (Leu/Val preferred) and P2 (Gly/Ala preferred), with the S2' position preferring Leu. Prime subsites collectively contribute to cleavage efficiency.\",\n      \"method\": \"Randomized phage display library, kinetic substrate assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic substrate library screening with kinetic validation; comprehensive active-site specificity mapping\",\n      \"pmids\": [\"16169853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Four positively charged residues on the C1s SP domain form a catalytic exosite required for efficient C4 cleavage; these residues coordinate a sulfate ion in the crystal structure. C1s interacts with a peptide from C4 containing three sulfotyrosine residues via this exosite.\",\n      \"method\": \"Site-directed mutagenesis, crystal structure analysis, peptide binding assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with structural and biochemical peptide binding data in a single study\",\n      \"pmids\": [\"22855709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"C1r CUB1 and CUB2 modules provide high-affinity C1q-binding sites, and C1s CUB1 provides lower-affinity sites; all sites involve acidic residues that also contribute Ca2+ ligands. Together the C1s-C1r-C1r-C1s tetramer contributes six C1q-binding sites, one per C1q stem. A previous model invoking ionic bonds from the C1r EGF Glu137-Glu-Asp139 stretch was ruled out by mutagenesis.\",\n      \"method\": \"Site-directed mutagenesis of C1r/C1s, SPR binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic mutagenesis with quantitative SPR, refuting prior model and establishing new one\",\n      \"pmids\": [\"19473974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"C1s is the serine protease secreted by human fibroblasts that cleaves insulin-like growth factor-binding protein-5 (IGFBP-5) but not IGFBP-1 through -4. C1r undergoes autoactivation in fibroblast medium and the activated form cleaves C1s; the activated C1s cleaves both C4 and IGFBP-5. C1 inhibitor inhibits this IGFBP-5 cleavage.\",\n      \"method\": \"Protein purification, immunoaffinity chromatography, amino acid sequencing, IGFBP-5 zymography, C4 cleavage assay, C1 inhibitor inhibition assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purification with sequence confirmation, multiple functional assays including inhibitor control\",\n      \"pmids\": [\"10982804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Activated C1s cleaves beta2-microglobulin at Lys-58, generating a two-chain modified form; this is the first demonstrated non-complement protein substrate for C1s. Cleavage is inhibited by C1 esterase inhibitor.\",\n      \"method\": \"In vitro protease assay, mass spectrometry (sequence analysis of cleavage products), C1 esterase inhibitor inhibition\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro cleavage with product characterization and inhibitor control\",\n      \"pmids\": [\"2110898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"C1s (both purified and as part of the C1 complex) cleaves the nuclear alarmin HMGB1 into defined 19 kDa and 12 kDa fragments, diminishing HMGB1's ability to enhance LPS-mediated pro-inflammatory cytokine production from monocytes, macrophages and dendritic cells. Mass spectrometry of C1 complex-treated apoptotic cell proteins identified additional intracellular C1s substrates.\",\n      \"method\": \"In vitro protease assay with purified C1s and C1 complex, SDS-PAGE, mass spectrometry, cytokine production assay\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro cleavage confirmed with both purified enzyme and physiological C1 complex, functional consequence measured\",\n      \"pmids\": [\"27648302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"C1s undergoes Ca2+-dependent self-association to form a dimer. The monomer has a single Ca2+-binding site (K ~3×10^5 M^-1); the dimer has three Ca2+-binding sites, with one high-affinity interfacial site (K ~1×10^8 M^-1) driving dimerization.\",\n      \"method\": \"Sedimentation equilibrium ultracentrifugation over wide concentration ranges\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative biophysical measurement with full thermodynamic model\",\n      \"pmids\": [\"1445906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"C1s inhibition by C1 inhibitor follows pure second-order kinetics with a bimolecular rate constant of 6.0×10^4 M^-1 s^-1 at 30°C, forming a covalent complex. Heparin accelerates the rate up to 35-fold and binds all three components (enzyme, inhibitor, complex) with similar affinity (Kd 2.0–3.3 μM).\",\n      \"method\": \"Continuous esterolytic activity monitoring, HPLC size-exclusion chromatography, fluorescence probes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal kinetic methods, quantitative characterization of inhibition mechanism\",\n      \"pmids\": [\"3091067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The B chain (serine protease domain) of C1s is structurally and functionally independent of the A chain interaction domain. A C1s derivative lacking most of the B chain (C1s-A) retains the ability to dimerize, form C1r2s2 tetramers, and associate with C1q, but is catalytically inactive. All C1q- and C1r-binding sites of C1s are located on the A chain.\",\n      \"method\": \"Trypsin-limited proteolysis, fast exclusion chromatography, thermal denaturation fluorimetry, functional reconstitution hemolytic assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain-deletion approach with multiple functional readouts demonstrating structural independence\",\n      \"pmids\": [\"2847785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"C1-inhibitor–C1s complexes are cleared in vivo via the low density lipoprotein receptor-related protein (LRP). Cellular degradation of C1-INH·C1s is inhibited by chloroquine and by receptor-associated protein (RAP, an LRP inhibitor); LRP-deficient fibroblasts do not degrade the complex. C1-INH·C1s does not stimulate neutrophil or monocyte chemotaxis.\",\n      \"method\": \"Cell binding assays (HepG2, neutrophils, monocytes), in vivo clearance with RAP inhibition, LRP-knockout fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacologic dissection with LRP-deficient cells; two orthogonal methods\",\n      \"pmids\": [\"9388254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"C1s activates the zymogen of matrix metalloproteinase 9 (MMP-9), suggesting coordinated participation of C1s and MMP-9 in cartilage matrix degradation.\",\n      \"method\": \"Immunohistochemistry, in vitro zymogen activation assay\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single in vitro activation assay supported by immunolocalization; single lab, limited functional follow-up\",\n      \"pmids\": [\"8082118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Chimeric C1s/MASP-2 molecules show that higher C4 cleavage efficiency of MASP-2 arises from the CCP modules (nanomolar vs micromolar Km with C4). C2 cleavage efficiency is determined by the SP domain. C1s CCP modules are not required for C1r binding, C1q association, or tetramer assembly.\",\n      \"method\": \"Baculovirus expression of chimeric proteins, kinetic substrate cleavage assays, C1 complex reconstitution\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — domain-swap chimeras with quantitative kinetic analysis and functional reconstitution\",\n      \"pmids\": [\"16227207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Recombinant C1s lacking beta-hydroxyasparagine at Asn134, sialic acid, and one N-linked carbohydrate chain (Asn159→Gln mutant) still reassembles with C1q and C1r to form functional C1 and initiates the classical complement pathway, demonstrating these post-translational modifications are not critical for C1 assembly or activation.\",\n      \"method\": \"Baculovirus expression, site-directed mutagenesis, sedimentation analysis, hemolytic assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct mutagenesis with functional reconstitution assay\",\n      \"pmids\": [\"1533159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"On cardiolipin (CL) vesicles, C1s can be activated independently of C1r: a C1q-dependent, Ca2+-sensitive binding of dimeric C1s to CL vesicles occurs, and bound C1s is specifically cleaved at 37°C into active 58 kDa and 28 kDa chains in the absence of C1r. Anti-CL antibodies inhibit this C1q-mediated C1s cleavage.\",\n      \"method\": \"Immunochemical analysis, SDS-PAGE, complement activation assays with C1 component depletion\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, biochemical fractionation with specific antibody inhibition controls, but unusual mechanism with limited replication\",\n      \"pmids\": [\"3029222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Active C1s (detected by activation-specific antibody M241) is present in degenerating cartilage of rheumatoid arthritis but not osteoarthritis. TNF-alpha increases C1s production by chondrocytes in vitro. Activated C1s in cartilage is proposed to participate in pathogenesis through collagenolytic activity.\",\n      \"method\": \"Immunohistochemistry with activation-state-specific monoclonal antibody, ELISA for cytokine regulation\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — in situ detection with activation-specific antibody and cytokine regulation experiment; functional mechanism inferred not directly demonstrated in cartilage\",\n      \"pmids\": [\"10364916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"C1s is synthesized and secreted by resting human monocytes; stimulation by lymphokine-conditioned media increases C1s secretion and also induces C1r and C1 inhibitor secretion. The whole C1 complex can potentially be assembled locally.\",\n      \"method\": \"Metabolic labeling, immunoprecipitation, SDS-PAGE, functional complement assays from monocyte cultures\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biosynthesis demonstrated by metabolic labeling and secretion assays; multiple cell conditions tested\",\n      \"pmids\": [\"6318736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Anti-C1-inhibitor autoantibodies prevent formation of stable covalent C1s–C1 inhibitor complexes by converting C1 inhibitor to a substrate: C1s cleaves C1 inhibitor but a stable covalent bond does not form. Peptides 2 (aa 438–449) and 3 (aa 448–459) of C1 inhibitor block autoantibody activity and restore C1s inhibition.\",\n      \"method\": \"SDS-PAGE complex analysis, esterolytic activity assays, peptide competition assays\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays with peptide competition confirming mechanism; single lab\",\n      \"pmids\": [\"9508789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Polyanions (dextran sulfate, heparin) bind C1s directly and exert a biphasic effect on its proteolytic activity (enhancement at low, inhibition at high concentrations). Polyanion-mediated acceleration of C1s–SERPING1 (C1 inhibitor) interaction requires both protease-polyanion and serpin-polyanion interactions.\",\n      \"method\": \"Kinetic inhibition assays, chimaeric alpha1-antitrypsin mutant unable to bind polyanions\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinetic assays with chimeric serpin control; single lab\",\n      \"pmids\": [\"19522701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Intradermal injection of C1s in guinea pigs causes increased vascular permeability; this effect requires complement component C2, as C2-deficient guinea pigs fail to show permeability increase. C2-deficient animals respond normally to bradykinin and kallikrein. Reconstitution with guinea pig C2 restores C1s-induced permeability.\",\n      \"method\": \"In vivo intradermal injection, genetic complement-deficient animals, component reconstitution\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with reconstitution, establishes C2 requirement downstream of C1s\",\n      \"pmids\": [\"3487577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Knockdown of C1s (and C1r) in cutaneous squamous cell carcinoma cells inhibited ERK1/2 and Akt activation, promoted apoptosis, and suppressed tumor growth and vascularization in xenograft models, demonstrating a tumor-cell-autonomous pro-survival signaling role for C1s.\",\n      \"method\": \"shRNA knockdown, Western blot for ERK/Akt, xenograft tumor growth assay\",\n      \"journal\": \"The British journal of dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific signaling readout and in vivo xenograft, but C1r and C1s were knocked down together, limiting attribution to C1s alone\",\n      \"pmids\": [\"31049937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Two pEDS-associated C1S missense mutations (p.Val316del and p.Cys294Arg) cause local CCP1 module misfolding, exposing a cryptic cleavage site (Lys353-Cys354). Cells expressing mutant C1s secrete only a truncated Fg40 fragment (40 kDa) containing the intact SP domain but lacking the N-terminal interaction domains. Fg40 retains esterolytic activity and HMGB1-cleaving activity but has impaired C4 activation; it escapes physiological control within the C1 complex.\",\n      \"method\": \"Cell transfection, recombinant protein purification, mass spectrometry, N-terminal sequencing, enzymatic activity assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two independent mutations studied with multiple orthogonal biochemical methods; rigorous functional characterization\",\n      \"pmids\": [\"31921203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"C1s (hamster/CHO-derived) is responsible for proteolysis of recombinant HIV gp120 in CHO cells at a specific serine-protease-sensitive epitope. CRISPR/Cas9 knockout of C1s in CHO cells eliminates this proteolytic clipping activity.\",\n      \"method\": \"CRISPR/Cas9 gene knockout, recombinant protein expression, Western blot analysis\",\n      \"journal\": \"Biotechnology and bioengineering\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with clear functional readout; single lab, substrate not a canonical C1s target\",\n      \"pmids\": [\"31087560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The human C1r and C1s genes are located in a tail-to-tail arrangement on chromosome 12p13, approximately 9.5 kb apart. Both genes are primarily expressed in liver; C1s mRNA undergoes alternative polyadenylation generating multiple transcript sizes.\",\n      \"method\": \"Southern blot, genomic DNA sequencing, RNA blot analysis, in situ hybridization\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct genomic and expression analysis with multiple complementary methods\",\n      \"pmids\": [\"2459702\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"C1s is a modular serine protease that circulates as a zymogen within the Ca2+-dependent C1s-C1r-C1r-C1s tetramer (assembled via CUB1-EGF-CUB2 head-to-tail heterodimer interfaces) associated with C1q; upon C1q binding to antibody–antigen complexes or other activating surfaces, C1r undergoes autoactivation and cleaves C1s at Arg422-Ile423 to generate the two-chain active enzyme, which then uses exosites on its CCP1-CCP2 modules and four positively charged residues on its SP domain to recognize and cleave C4 (releasing C4a and C4b) and C2, propagating the classical complement cascade; C1s activity is tightly regulated by C1 inhibitor (SERPING1), which forms a 1:1 covalent SDS-stable complex with the C1s light chain and is cleared via LRP, while heparin/polyanions accelerate this inhibition; beyond complement substrates, C1s also cleaves IGFBP-5, beta2-microglobulin, HMGB1, and MMP-9 zymogen, and gain-of-function mutations in C1S associated with periodontal Ehlers-Danlos syndrome cause CCP1 misfolding that generates a truncated, unregulated SP fragment with altered substrate specificity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"C1S encodes a modular serine protease that serves as the catalytic effector of the classical complement pathway, circulating as a zymogen within the Ca2+-dependent C1s-C1r-C1r-C1s tetramer associated with C1q [#7, #8]. C1s is built from an N-terminal interaction region (two EGF-like and two CCP modules plus CUB domains) and a C-terminal trypsin-like serine protease domain [#4], and its CUB1-EGF and CUB1-EGF-CUB2 interfaces drive Ca2+-dependent self-association and preferential C1r-C1s heterodimer formation that organizes the compact ring-shaped C1 complex and presents six C1q-binding sites, one per C1q collagen stem [#5, #8, #12]. The protease's interaction sites for C1q and C1r reside entirely on the A chain, structurally independent of the catalytic B chain [#18]. Within C1, surface-bound C1q triggers C1r autoactivation, which cleaves C1s to generate the two-chain active enzyme [#0]; activation repositions zymogen SP-domain loops that otherwise sterically block C4 binding [#6]. Active C1s then propagates the cascade by cleaving C4 and C2 (generating C2a and C2b, the latter bearing the C4b-binding site) to assemble the C3 convertase [#0, #1]. Efficient C4 recognition depends on cooperating exosites — the CCP1-CCP2 junction and four positively charged SP-domain residues that engage sulfotyrosine residues on C4 — whereas C2 cleavage is governed by the SP domain alone [#6, #9, #11, #21], and intrinsic active-site specificity favors Arg/Lys at P1 [#10]. C1s activity is controlled by C1 inhibitor (SERPING1), which forms a stable 1:1 covalent SDS-resistant complex with the C1s light chain following second-order kinetics that heparin and polyanions accelerate; the resulting complexes are cleared via LRP [#2, #17, #19, #27]. Beyond complement, C1s cleaves non-canonical substrates including IGFBP-5, beta2-microglobulin, the alarmin HMGB1, and the zymogen of MMP-9, linking the protease to growth-factor signaling, inflammation, and matrix degradation [#13, #14, #15, #20]. Gain-of-function C1S mutations associated with periodontal Ehlers-Danlos syndrome cause CCP1 misfolding that exposes a cryptic cleavage site, yielding a truncated, unregulated SP fragment (Fg40) with retained esterolytic and HMGB1-cleaving activity but impaired C4 activation that escapes control within the C1 complex [#30].\",\n  \"teleology\": [\n    {\n      \"year\": 1977,\n      \"claim\": \"Established that C1s is a two-chain trypsin-like serine protease with narrow specificity that is generated by C1r cleavage and acts on the complement substrates C4 and C2, defining its core enzymatic identity and cascade position.\",\n      \"evidence\": \"SDS-PAGE, N-terminal sequencing, and esterolytic/cleavage assays on purified C1s, plus C2 fragment characterization by electrophoresis and C4b-Sepharose binding\",\n      \"pmids\": [\"869924\", \"70787\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain organization and structural basis of specificity not yet resolved\", \"Mechanism of activation within the assembled C1 complex not addressed\"]\n    },\n    {\n      \"year\": 1975,\n      \"claim\": \"Identified C1 inhibitor as the physiological regulator of C1s, forming a stable conformation-dependent 1:1 covalent complex via the C1s light chain — the founding observation of complement protease control.\",\n      \"evidence\": \"SDS-PAGE, size-exclusion chromatography, and activity assays with acid-denaturation controls\",\n      \"pmids\": [\"123251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics and rate of inhibition not quantified\", \"In vivo fate of the inhibited complex unknown\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Determined the complete primary sequence and modular domain architecture of C1s (EGF, CCP, and SP domains), providing the framework for mapping interaction versus catalytic functions.\",\n      \"evidence\": \"cDNA cloning and nucleotide sequencing from a human liver library with amino acid sequence validation\",\n      \"pmids\": [\"3500856\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional contribution of individual domains not yet dissected\", \"Three-dimensional structure unresolved\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Localized all C1q- and C1r-binding capacity to the A chain and showed the catalytic B chain is structurally independent, separating assembly functions from proteolysis; also mapped the C1r/C1s gene pair to chromosome 12p13 with liver-predominant expression.\",\n      \"evidence\": \"Limited proteolysis, exclusion chromatography, hemolytic reconstitution; genomic Southern/RNA blot and in situ hybridization\",\n      \"pmids\": [\"2847785\", \"2459702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic details of the interaction interfaces not yet defined\", \"Regulation of tissue-specific expression not addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Quantified Ca2+-dependent C1s self-association and showed that catalytic post-translational modifications (beta-hydroxylation, sialylation, one N-glycan) are dispensable for C1 assembly and activation, clarifying which features are essential for function.\",\n      \"evidence\": \"Sedimentation equilibrium ultracentrifugation; baculovirus expression with site-directed mutagenesis and hemolytic assays\",\n      \"pmids\": [\"1445906\", \"1533159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the high-affinity interfacial Ca2+ site not resolved\", \"Role of glycans in stability/secretion not examined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that both CCP modules are required for efficient C4 cleavage (~70-fold loss without CCP1) while C2 cleavage is CCP-independent, establishing that the CCP modules carry C4-specific substrate-recognition exosites.\",\n      \"evidence\": \"Baculovirus expression of truncated recombinant C1s with quantitative cleavage assays\",\n      \"pmids\": [\"9422791\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of the CCP exosite contacts not defined\", \"Generalizability to other substrates untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Solved the CUB1-EGF structure showing a Ca2+-stabilized head-to-tail homodimer and a novel Ca2+-binding CUB module, providing the structural basis for Ca2+-dependent C1r-C1s association and C1q binding.\",\n      \"evidence\": \"X-ray crystallography at 1.5 Å with Ca2+ coordination analysis\",\n      \"pmids\": [\"12788922\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterodimer (vs homodimer) interface not yet captured\", \"Arrangement within the intact tetramer unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapped active-site specificity (P1 Arg/Lys dominant) and used C1s/MASP-2 chimeras to localize C4-cleavage efficiency to the CCP modules and C2-cleavage efficiency to the SP domain, partitioning substrate selectivity across the molecule.\",\n      \"evidence\": \"Randomized phage display library with kinetics; baculovirus chimeric proteins with kinetic cleavage assays and C1 reconstitution\",\n      \"pmids\": [\"16169853\", \"16227207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic contacts of the CCP-mediated C4 exosite not yet visualized\", \"Determinants of non-complement substrate selection not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified four positively charged SP-domain residues forming a catalytic exosite that engages sulfotyrosines on C4, providing the molecular basis for high-efficiency C4 recognition beyond the active site.\",\n      \"evidence\": \"Site-directed mutagenesis, crystallographic sulfate coordination, and peptide binding assays\",\n      \"pmids\": [\"22855709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coordination of SP exosite with CCP exosite during catalysis not fully integrated\", \"Contribution to C2 cleavage not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the structural logic of zymogen-to-active transition and the architecture of C1: zymogen SP loops sterically block C4 binding until activation, and C1q stems contact CUB-module lysines/acidic residues to organize the compact head-to-tail tetramer poised for activation.\",\n      \"evidence\": \"X-ray crystallography of zymogen CCP1-CCP2-SP and of C1s–collagen/tetramer complexes, with SPR and mutagenesis validation\",\n      \"pmids\": [\"23592783\", \"23922389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamic conformational steps of in-situ activation not directly observed\", \"How surface binding mechanically triggers C1r remained partly inferred\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the C1r-C1s CUB1-EGF-CUB2 heterodimer as an antiparallel L-shaped, Ca2+-bridged assembly with more extensive contacts than homodimers, explaining preferential heterocomplex formation and proposing activation by separation of dimer pairs upon C1q surface binding.\",\n      \"evidence\": \"X-ray crystallography and biophysical analysis\",\n      \"pmids\": [\"29311313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct visualization of the activation conformational change in intact C1 not achieved\", \"Kinetics of the dimer-separation step not measured\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that C1-inhibitor·C1s complexes are catabolized via the LRP receptor, defining the clearance route for spent protease-inhibitor complexes.\",\n      \"evidence\": \"Cell binding assays, in vivo clearance with RAP inhibition, and LRP-deficient fibroblasts\",\n      \"pmids\": [\"9388254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"LRP-binding determinants on the complex not mapped\", \"Quantitative contribution relative to other clearance routes unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Quantified C1 inhibitor as a covalent second-order inactivator of C1s and showed heparin accelerates inhibition up to 35-fold, defining a tunable regulatory mechanism later extended to other polyanions.\",\n      \"evidence\": \"Esterolytic kinetics, HPLC size-exclusion, fluorescence probes; later kinetic assays with a polyanion-binding-deficient chimeric serpin\",\n      \"pmids\": [\"3091067\", \"19522701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological polyanion(s) modulating C1s in vivo not identified\", \"Biphasic concentration dependence mechanism only partly explained\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed anti-C1-inhibitor autoantibodies convert C1 inhibitor into a cleavable substrate that fails to form a stable covalent complex, defining an acquired mechanism of dysregulated C1s activity.\",\n      \"evidence\": \"SDS-PAGE complex analysis, esterolytic assays, and peptide competition mapping\",\n      \"pmids\": [\"9508789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without independent replication\", \"In vivo relevance to specific patient phenotypes not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended C1s function beyond complement by identifying it as the fibroblast protease that selectively cleaves IGFBP-5, linking C1s to growth-factor bioavailability under C1-inhibitor control.\",\n      \"evidence\": \"Protein purification, sequencing, IGFBP-5 zymography, C4 cleavage and C1-inhibitor inhibition assays\",\n      \"pmids\": [\"10982804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological/in vivo significance of IGFBP-5 cleavage not established\", \"Selectivity determinants for IGFBP-5 over IGFBP-1–4 not defined\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Identified beta2-microglobulin (cleaved at Lys-58) as the first non-complement protein substrate of C1s, broadening the recognized substrate repertoire.\",\n      \"evidence\": \"In vitro protease assay with product sequencing and C1 esterase inhibitor control\",\n      \"pmids\": [\"2110898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biological consequence of beta2-microglobulin cleavage not determined\", \"In vivo occurrence not demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed that C1s, both purified and within the C1 complex, cleaves the alarmin HMGB1 into defined fragments that lose pro-inflammatory cytokine-enhancing activity, and identified additional intracellular substrates, implicating C1s in modulating inflammation during apoptotic-cell handling.\",\n      \"evidence\": \"In vitro protease assays, mass spectrometry, and monocyte/macrophage/DC cytokine production assays\",\n      \"pmids\": [\"27648302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution to inflammation resolution not established\", \"Functional impact of the additional intracellular substrates not characterized\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided the molecular basis of periodontal Ehlers-Danlos syndrome by showing pEDS C1S mutations misfold CCP1, exposing a cryptic cleavage site that yields a truncated, regulation-escaping SP fragment with altered substrate behavior.\",\n      \"evidence\": \"Cell transfection, recombinant purification, mass spectrometry, N-terminal sequencing, and enzymatic assays on two independent mutants\",\n      \"pmids\": [\"31921203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo substrate spectrum and tissue consequences of Fg40 not defined\", \"Link between altered proteolysis and connective-tissue pathology mechanistically incomplete\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Reported that C1s activates the MMP-9 zymogen, proposing a role in cartilage matrix degradation alongside complement-independent proteolysis.\",\n      \"evidence\": \"Immunohistochemistry and in vitro zymogen activation assay\",\n      \"pmids\": [\"8082118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro activation assay with limited functional follow-up\", \"In vivo relevance to matrix turnover not demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Implicated C1s in tumor-cell-autonomous pro-survival signaling, where knockdown reduced ERK/Akt activation, increased apoptosis, and suppressed xenograft tumor growth.\",\n      \"evidence\": \"shRNA knockdown, Western blot for ERK/Akt, and xenograft assays in cutaneous SCC cells\",\n      \"pmids\": [\"31049937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"C1r and C1s knocked down together, limiting attribution to C1s alone\", \"Molecular link between C1s proteolysis and ERK/Akt signaling undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how C1s's non-complement substrate cleavages (IGFBP-5, beta2-microglobulin, HMGB1, MMP-9) and its tumor pro-survival signaling role operate in vivo, and how substrate selection is governed outside the canonical C4/C2 exosite framework.\",\n      \"evidence\": \"No direct in vivo mechanistic study in the timeline integrates these activities\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No in vivo demonstration of physiological non-complement substrate cleavage\", \"Signaling mechanism downstream of C1s in tumor cells unmapped\", \"Substrate-recognition rules for non-complement targets undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 9, 10, 11, 13, 14, 15, 20, 30]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13, 25, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [9, 13, 14, 15, 20]}\n    ],\n    \"complexes\": [\n      \"C1 complex (C1q-C1r2-C1s2)\",\n      \"C1s-C1r-C1r-C1s tetramer\",\n      \"C1s–C1 inhibitor (SERPING1) covalent complex\"\n    ],\n    \"partners\": [\n      \"C1R\",\n      \"C1QA\",\n      \"C4\",\n      \"C2\",\n      \"SERPING1\",\n      \"LRP1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}